Delivery Order SPE2DB22D1017-SPE2DB25FYNZR
- Not listed
- The Defense Logistics Agency awarded a $47,709.15 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml SureClick auto-injectors, with an ultimate completion date of August 25, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The place of performance is listed as AmerisourceBergen's corporate headquarters location in Conshohocken, PA. This...
- The Defense Logistics Agency (DLA) awarded a $35,072.01 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors, with an ultimate completion date of August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded a $13,844.92 delivery order to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This non-set-aside, competitively awarded contract utilized firm fixed pricing and was completed on July 24, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of the company's established role as a critical pharmaceutical supplier to the...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors valued at $9,253.56 on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price, non-competitive delivery order represents pharmaceutical procurement for military healthcare needs and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,183.90 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This firm fixed-price delivery order, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major...
- The Defense Logistics Agency awarded a $21,861.17 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors on August 11, 2025, with completion targeted for August 12, 2025. This competitively awarded, firm fixed-price delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs. The contract is performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company maintains operations as...
- The Defense Logistics Agency awarded a delivery order valued at $7,887.13 to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml SureClick auto-injectors, with an ultimate completion date of July 28, 2025. This non-competitive delivery order represents a firm fixed-price transaction issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $13,729.56 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injectors. The contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. The delivery order is set to be completed by July 31, 2025, and will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction within a...
- The Defense Logistics Agency (DLA) awarded a $30,241.74 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml SureClick auto-injectors, with an ultimate completion date of August 26, 2025. This firm fixed-price contract, awarded on August 25, 2025, represents a non-set-aside competitive award under the DLA's pharmaceutical procurement framework. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters...
- The Defense Logistics Agency awarded a $22,169.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors, with a completion date of July 25, 2025. This contract, executed on July 24, 2025, represents a non-set-aside competitive award and reflects the agency's procurement of specialty pharmaceutical products for military and federal healthcare systems. The delivery location is specified as AmerisourceBergen's corporate office in Conshohocken,...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYNZRDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,581.14 to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors, with a completion date of August 26, 2025. This non-competitive delivery order was issued under a firm fixed-price arrangement and represents a single transaction within DLA's broader pharmaceutical procurement operations. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC, designated SPE2DX, serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to military healthcare programs worldwide. Enbrel, a biologic immunosuppressant used to treat rheumatoid arthritis and other autoimmune conditions, is a critical specialty pharmaceutical within the Defense Health Agency's formulary for treating service members and beneficiaries requiring advanced therapeutic interventions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.6k | 8/25/25 |